Evidence map›Paper›PMID 26624227›Full record

ArticleNature communications2015

ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy.

Ronald A Albright, Paul Stabach, Wenxiang Cao, Dillon Kavanagh, Isabelle Mullen, Alexander A Braddock, Mariel S Covo, Martin Tehan, Guangxiao Yang, Zhiliang Cheng and 12 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03478839 (A Natural History Study of Patients With Generalized Arterial Calcification of Infancy), which is not on this map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03478839 completednot on this mapstarted 2018, after this paper: background citation

A Natural History Study of Patients With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)

TypeobservationalSponsorNational Human Genome Research Institute (NHGRI)Ran2018 to 2020Enrolled48ConditionsGeneralized Arterial Calcification of Infancy, Autosomal Recessive Hypophosphatemic Rickets Type2
3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 140 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Hypophosphatemic rickets: diagnosis and treatment.Archives of endocrinology and metabolism · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Six cases ofJBMR plus · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Elevated phosphate levels in CKD - a direct threat for the heart.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  17. Article
  18. Review
  19. Review
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Ronald A AlbrightDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Paul StabachDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Wenxiang CaoDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, USA.
Dillon KavanaghDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Isabelle MullenDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Alexander A BraddockDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Mariel S CovoDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Martin TehanDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Guangxiao YangDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Zhiliang ChengAlexion, Cheshire, Connecticut 06410, USA.
Keith BouchardAlexion, Cheshire, Connecticut 06410, USA.
Zhao-Xue YuAlexion, Cheshire, Connecticut 06410, USA.
Stephanie ThornDepartment of Medicine and Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Xiangning WangDepartment of Medicine and Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Ewa J Folta-StogniewWM Keck Biotechnology Research Laboratory, Yale University School of Medicine, New Haven, Connecticut 06511, USA.
Alejandro NegreteBiotechnology Core Laboratory, National Institute of Diabetes and Digestive Kidney Diseases, National Institutes of Health, Rockville, Maryland 20852, USA.
Albert J SinusasDepartment of Medicine and Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Joseph ShiloachBiotechnology Core Laboratory, National Institute of Diabetes and Digestive Kidney Diseases, National Institutes of Health, Rockville, Maryland 20852, USA.
George ZubalZ-Concepts LLC, East Haven, Connecticut 06512, USA.
Joseph A MadriDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Enrique M De La CruzDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, USA.
Demetrios T BraddockDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Yale University · USAlexion Pharmaceuticals (United States) · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · US

Funding

Large-scale production and purification of biological compoundsZIBDK015500 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SHILOACH, JOSEPH · 2015 to 2016
$1.2M
6 · The paper itself

Abstract

Diseases of ectopic calcification of the vascular wall range from lethal orphan diseases such as generalized arterial calcification of infancy (GACI), to common diseases such as hardening of the arteries associated with aging and calciphylaxis of chronic kidney disease (CKD). GACI is a lethal orphan disease in which infants calcify the internal elastic lamina of their medium and large arteries and expire of cardiac failure as neonates, while calciphylaxis of CKD is a ubiquitous vascular calcification in patients with renal failure. Both disorders are characterized by vascular Mönckeburg's sclerosis accompanied by decreased concentrations of plasma inorganic pyrophosphate (PPi). Here we demonstrate that subcutaneous administration of an ENPP1-Fc fusion protein prevents the mortality, vascular calcifications and sequela of disease in animal models of GACI, and is accompanied by a complete clinical and biomarker response. Our findings have implications for the treatment of rare and common diseases of ectopic vascular calcification.

Indexed as

AnimalsArteriesDisease Models, AnimalFemaleHumansImmunoglobulin Fc FragmentsImmunoglobulin GInfant, NewbornInfant, Newborn, DiseasesMaleMice, Inbred C57BLPhosphoric Diester HydrolasesPyrophosphatasesVascular Calcificationectonucleotide pyrophosphatase phosphodiesterase 1Immunoglobulin Fc FragmentsImmunoglobulin GPhosphoric Diester HydrolasesPyrophosphatases

Identifiers

PMID26624227
PMCPMC4686714
OpenAlexW2261704194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.